Renaissance Technologies’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $502K | Buy |
147,700
+200
| +0.1% | +$679 | ﹤0.01% | 2600 |
|
|
2025
Q4 | $420K | Sell |
147,500
-1,400
| -0.9% | -$3.61K | ﹤0.01% | 2641 |
|
|
2025
Q3 | $393K | Buy |
148,900
+4,700
| +3% | +$10.4K | ﹤0.01% | 2891 |
|
|
2025
Q2 | $324K | Buy |
144,200
+1,700
| +1% | +$3.75K | ﹤0.01% | 3017 |
|
|
2025
Q1 | $305K | Sell |
142,500
-9,308
| -6% | -$21.5K | ﹤0.01% | 2920 |
|
|
2024
Q4 | $367K | Sell |
151,808
-93,492
| -38% | -$222K | ﹤0.01% | 2972 |
|
|
2024
Q3 | $599K | Buy |
245,300
+14,500
| +6% | +$35.4K | ﹤0.01% | 2700 |
|
|
2024
Q2 | $593K | Buy |
230,800
+108,700
| +89% | +$258K | ﹤0.01% | 2616 |
|
|
2024
Q1 | $357K | Sell |
122,100
-218,973
| -64% | -$612K | ﹤0.01% | 3011 |
|
|
2023
Q4 | $788K | Buy |
341,073
+296,773
| +670% | +$634K | ﹤0.01% | 2548 |
|
|
2023
Q3 | $116K | Buy |
44,300
+10,600
| +31% | +$33.4K | ﹤0.01% | 3216 |
|
|
2023
Q2 | $121K | Buy |
33,700
+21,800
| +183% | +$69.9K | ﹤0.01% | 3429 |
|
|
2023
Q1 | $26K | Buy |
+11,900
| New | +$37.8K | ﹤0.01% | 3783 |
|
|
2022
Q3 | – | Sell |
-359,697
| Closed | -$1.65M | – | 4317 |
|
|
2022
Q2 | $1.65M | Buy |
+359,697
| New | +$1.92M | ﹤0.01% | 2336 |
|
|
2022
Q1 | – | Sell |
-203,200
| Closed | -$2.9M | – | 4362 |
|
|
2021
Q4 | $2.9M | Buy |
+203,200
| New | +$4.25M | ﹤0.01% | 1867 |
|
|
2021
Q1 | – | Sell |
-372,415
| Closed | -$1.58M | – | 3597 |
|
|
2020
Q4 | $1.58M | Sell |
372,415
-96,200
| -21% | -$313K | ﹤0.01% | 2266 |
|
|
2020
Q3 | $1.22M | Buy |
468,615
+244,300
| +109% | +$851K | ﹤0.01% | 2407 |
|
|
2020
Q2 | $792K | Buy |
224,315
+35,900
| +19% | +$120K | ﹤0.01% | 2666 |
|
|
2020
Q1 | $573K | Sell |
188,415
-39,310
| -17% | -$172K | ﹤0.01% | 2693 |
|
|
2019
Q4 | $1.17M | Buy |
227,725
+15,800
| +7% | +$59.2K | ﹤0.01% | 2556 |
|
|
2019
Q3 | $676K | Buy |
211,925
+53,827
| +34% | +$179K | ﹤0.01% | 2749 |
|
|
2019
Q2 | $568K | Buy |
158,098
+53,043
| +50% | +$187K | ﹤0.01% | 2936 |
|
|
2019
Q1 | $382K | Buy |
105,055
+46,527
| +79% | +$154K | ﹤0.01% | 3029 |
|
|
2018
Q4 | $176K | Buy |
58,528
+17,683
| +43% | +$73.2K | ﹤0.01% | 3158 |
|
|
2018
Q3 | $199K | Sell |
40,845
-12,255
| -23% | -$63.6K | ﹤0.01% | 3155 |
|
|
2018
Q2 | $395K | Sell |
53,100
-16,700
| -24% | -$121K | ﹤0.01% | 2899 |
|
|
2018
Q1 | $454K | Sell |
69,800
-23,700
| -25% | -$183K | ﹤0.01% | 2944 |
|
|
2017
Q4 | $842K | Buy |
93,500
+10,500
| +13% | +$100K | ﹤0.01% | 2731 |
|
|
2017
Q3 | $824K | Buy |
83,000
+57,900
| +231% | +$499K | ﹤0.01% | 2639 |
|
|
2017
Q2 | $195K | Buy |
+25,100
| New | +$189K | ﹤0.01% | 3000 |
|
Other funds holding ORMP
BCM
AF
GIA
M
BFM
RG
Renaissance Technologies's ORMP Position: Q1 2026 in Review
Renaissance Technologies increased its Oramed Pharmaceuticals (ORMP) stake by 0.14% in Q1 2026, buying an estimated $679 and bringing the position to 147,700 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #2600.
Renaissance Technologies first reported a position in ORMP in Q2 2017 and has held it in 30 quarters since. The position peaked at $2.9M in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.
- Renaissance Technologies held 147,700 shares of Oramed Pharmaceuticals worth $502K as of Q1 2026.
- Renaissance Technologies bought 200 Oramed Pharmaceuticals shares in Q1 2026, an estimated $679.
- Oramed Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2600 holding.
- Renaissance Technologies first reported a position in Oramed Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
- Renaissance Technologies's Oramed Pharmaceuticals position peaked at $2.9M in Q4 2021.
- 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.